All In Biotech

Drug Trial Radar · NCT05345509

A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.

A Phase 1, Randomized, Open-Label, Exploratory, Sequential, Pharmacokinetic Single Ascending Dose Study of IVL3003 Versus Multiple Doses of Aricept (Donepezil) Tablets in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

62

Planned (sponsor's estimate)

Start

Apr 1, 2023

Primary completion

Nov 13, 2025

Study completion Nov 13, 2025

Sponsor

Lead sponsor
Inventage Lab., Inc.Industry
Sponsor type
Industry
First posted
Apr 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Clinical Trial to Assess Pharmacokinetic Profiles and Safety of IVL3003

Conditions

  • Alzheimer Disease

Interventions

  • Aricept TabletDrug

    Donepezil Tablet once daily P.O

  • IVL3003Drug

    Donepezil Long-Acting Injection, once S.C Injection

  • IVL3003Drug

    Donepezil Long-Acting Injection, once IM Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUClast of IVL3003Time frame: Pre-dose, up to 1month
  2. AUCinf of IVL3003Time frame: Pre-dose, up to 1month
  3. AUClast of AriceptTime frame: Pre-dose, up to 1month
  4. AUCinf of AriceptTime frame: Pre-dose, up to 1month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Melbourne, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.